Events & Presentations

Investors

Events & Presentations

Upcoming Events
Date Event Details Remind Me
Mar 26, 2019 4:35 PM EDT
Oligonucleotide & Precision Therapeutics (OPT) Congress
James Hamilton, M.D., Arrowhead’s vice president of clinical development, will deliver an oral presentation titled, “siRNA Clinical Development Based on the TRiMTM Platform”
Cambridge, MA
Mar 27 - Mar 30, 2019
CSHL Meeting: RNA & Oligonucleotide Therapeutics
Dr. Hamilton will deliver an oral presentation titled, “Cardiovascular and lipid disorders - A next frontier for TRiMTM RNAi”
Cold Spring Harbor, NY
Apr 3, 2019 8:00 AM EDT
AACR Annual Meeting 2019
So Wong, Ph.D., Arrowhead’s director of oncology, will deliver a poster presentation titled, “Optimizing the potency and dosing design for ARO-HIF2: An RNAi therapeutic for clear cell renal cell carcinoma”
Apr 10, 2019
The EASL International Liver Congress 2019

Oral Presentation:
Short term RNA interference therapy in chronic hepatitis B using JNJ-3989 brings majority of patients to HBsAg <100 IU/mL threshold

  • Presentation Reference: PS-080
  • Session: Parallel session: Hepatitis B - drug development
  • Date and Time: April 12, 2019 at 5:45 p.m. CET
  • Authors: Man-Fung Yuen, et al.

Poster Presentation:
Reduction of hepatic Z-alpha1 antitrypsin by RNA interference (RNAi) prevents and reverses liver disease including hepatic mitochondrial injury in the PiZ mouse model

  • Presentation Reference: FRI-446
  • Session: Poster: Rare liver diseases (including pediatric and genetic)
  • Session Date and Time: April 12, 2019 from 9 a.m. to 5 p.m. CET
  • Authors: Christine Wooddell, et al.
Archived Events
Date Event Details
Jun 10, 2016 10:30 AM EDT
Jefferies 2016 Healthcare Conference
New York
May 28 - May 29, 2016 12:00 AM EDT
5th Asian Conference on Hepatitis and AIDS (ACHA)

May 29, 4:50 p.m. CST (China Standard Tim) – Bruce Given, M.D., Arrowhead chief operating officer will deliver an oral presentation titled, “RNAi therapeutics for chronic HBV - Animal models”

May 10, 2016 4:30 PM EDT
Arrowhead Fiscal 2016 Second Quarter Results
May 9 - May 12, 2016 12:00 AM EDT
IBC's 18th Annual TIDES: Oligonucleotide and Peptide Therapeutics
Long Beach, California
May 9, 1:30 p.m. PDT – David Rozema, Ph.D., Arrowhead vice president of chemistry will deliver an oral presentation titled, “Protease-sensitive endosomal escape for delivery of siRNA in vivo”
 
May 9, 1:30 p.m. PDT – Qingguo Tian, Ph.D., Arrowhead bioanalytical project manager will deliver an oral presentation titled, “Sensitive and specific quantification of oligonucleotides in biological matrices using hybridization based LC-fluorescence assays”
 
May 5 - May 7, 2016 12:00 AM EDT
Arteriosclerosis, Thrombosis and Vascular Biology | Peripheral Vascular Disease (ATVB|PVD) 2016 Scientific Sessions
Nashville

May 6, 11:00 a.m. CDT – Stacey Melquist, Ph.D., Arrowhead senior scientist, and coauthors, will deliver a poster presentation titled, “Lipoprotein(a) targeting with RNAi delivery platforms in transgenic mice and cynomolgus monkeys” (Presentation Number 428)

Apr 16 - Apr 20, 2016 12:00 AM EDT
American Association for Cancer Research Annual Meeting 2016 (AACR16)
New Orleans

April 18, 1:00 p.m. CDT – So Wong, Ph.D., Arrowhead director of oncology, and coauthors, will deliver a poster presentation titled, “Novel HIF-2α targeted RNAi therapeutic for renal cell carcinoma” (abstract 2064)

Apr 13 - Apr 17, 2016 12:00 AM EDT
The International Liver Congress&#8482; 2016 (ILC 2016) &#150; The Annual Meeting of the European Association for the Study of the Liver
Barcelona, Spain

April 14, 8:00 a.m. CEST – Zhao Xu, Ph.D., Arrowhead senior scientist, and coauthors, will deliver a poster presentation titled, “Treatment of chronically HBV-infected chimpanzees with RNA interference therapeutic ARC-520 led to potent reduction of viral mRNA, DNA and proteins without observed drug resistance” (abstract THU-213)

April 14, 8:00 a.m. CEST – Man-Fung Yuen, M.D., Ph.D., chair of gastroenterology and hepatology, The University of Hong Kong, and deputy chief of service, Queen Mary Hospital department of medicine, Hong Kong, and coauthors, will deliver a poster presentation titled, “Differential reductions in viral antigens expressed from cccDNA vs integrated DNA in treatment naïve HBeAg positive and negative patients with chronic HBV after RNA interference therapy with ARC-520” (abstract THU-193)

April 15, 8:00 a.m. CEST – Renae Walsh, Ph.D., senior scientist, Victorian Infectious Diseases Reference Laboratory, and coauthors, will deliver a poster presentation titled, “Predicting HBsAg clearance responses during ARC-520 RNA interference (RNAi) therapy based on HBsAg epitope profile analysis” (abstract FRI-144)

Mar 15 - Mar 17, 2016 12:00 AM EDT
Barclays Global Healthcare Conference
Miami
March 17, 10:15 a.m. EST – Chris Anzalone, Ph.D., Arrowhead president and chief executive officer, will present a company overview
Mar 7 - Mar 9, 2016 12:00 AM EST
Cowen and Company 36th Annual Healthcare Conference
Boston
March 7, 4:00 p.m. EST – Chris Anzalone, Ph.D., Arrowhead president and chief executive officer, will present a company overview
Mar 4 - Mar 7, 2016 12:00 AM EST
2016 American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Meeting
Los Angeles
March 7, 9:45 a.m. PST – Stacey Melquist, Ph.D., Arrowhead senior scientist, and coauthors, will deliver a poster presentation titled, “Targeting Factor 12 (F12) with a Novel RNAi Delivery Platform As a Prophylactic Treatment for Hereditary Angioedema (HAE)”